Company Overview
| Stock Name | Vincent Med |
|---|---|
| Stock Code | 01612 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們為OEM客戶製造各種醫療器械(主要為呼吸產品、造影劑壓力注射器一次性產品以及骨科支護具康復器具),並以自有品牌「英仕醫療」開發、製造及銷售呼吸設備、一次性產品以及骨科支護具康復器具。 |
| Listing Date | 2016-07-13 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港九龍紅磡德豐街22號海濱廣場2座16樓1604-07A室 |
| Business Address (Hong Kong) | 香港紅磡鶴園街2G號恆豐工業大廈2期7樓B2室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | vincentmedical.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 1.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 0.01 / shares |
| Offer Period | 2016-06-30 to 2016-07-06 |
| Global Offering Shares | 127,600,000 shares |
| HK Public Offer Shares (Initial) | 12,760,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 114,840,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 638,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 127,600,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 524M |
| Est. Threshold | HK$ 9.69B |
| Analysis Result | HK market cap below threshold, need +1749% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 717,750,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約71.7百萬港元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
HKD
Income Statement
| Item | 2013 | 2014 | 2015 |
|---|---|---|---|
| Profit for the year | 27,010 | 42,396 | 71,656 |
Balance Sheet
| Item | 2013 | 2014 | 2015 |
|---|---|---|---|
| Cash and cash equivalents | 68,754 | 61,862 | 69,303 |
| Trade and bills receivables | 76,890 | 89,226 | 87,188 |
| Inventories | 39,926 | 66,518 | 65,422 |
| Total current assets | 200,912 | 232,964 | 238,575 |
| Total assets | 240,701 | 296,385 | 319,968 |
| Total current liabilities | 93,803 | 127,687 | 96,903 |
| Total equity | 146,898 | 168,698 | 217,087 |
| Equity attributable to owners | 120,271 | 138,533 | 169,358 |
| Interest-bearing borrowings | 1,800 | 600 | 4,717 |
Cash Flow Statement
| Item | 2013 | 2014 | 2015 |
|---|---|---|---|
| Net cash from operating activities | 41,251 | 43,997 | 54,551 |
| Net cash from investing activities | -9,551 | -29,302 | -15,569 |
| Net cash from financing activities | -20,654 | -21,201 | -25,204 |
| Net increase in cash | 11,046 | -6,506 | 13,778 |
| Depreciation of PP&E | 10,824 | 12,370 | 13,216 |
| Amortisation of intangible assets | 0 | 0 | 96 |
| Purchase of PP&E | -9,844 | -22,730 | -11,320 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 0.94 |
|---|---|
| First Day Open | HK$ 0.99 |
| First Day Change | -6.00% |
| First Day Volume | 31090000.0 |
| First Day Turnover | 29420600.0 |
| Use of Proceeds | 1、約50.0%或47.9百萬港元用于2016年至2018年擴充及升級生產設施;
2、約27.0%或25.8百萬港元用于2016年至2018年開發在研及計劃中產品;
3、約18.0%或17.2百萬港元,用于2016年至2018年銷售及營銷;
4、約5.0%或4.8百萬港元,用于一般公司用途及營運資金。 |
Underwriting Syndicate
Sole Sponsor (1)
BOSC International Company Limited CE BDP643
Overall Coordinators (1)
BOSC International Company Limited CE BDP643
Joint Bookrunners (3)
Joint Lead Managers (5)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 蔡文成 | — |
| Company Secretary | 徐麗琪 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | VRI持有59.87%;蔡先生及廖女士被視為透過VRI持有59.87%;IGF持有9.60%;珠海華發集團有限公司及陳友正先生被視為透過IGF持有9.60%。 |
|---|




